Compare · MRSN vs NVO
MRSN vs NVO
Side-by-side comparison of Mersana Therapeutics Inc. (MRSN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRSN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 617.4x MRSN ($310.7M).
- Over the past year, MRSN is up 199.9% and NVO is down 45.7% - MRSN leads by 245.5 points.
- NVO has hit the wire 8 times in the past 4 weeks while MRSN has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 22 for MRSN).
- Company
- Mersana Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $29.11+0.76%
- $41.01-4.51%
- Market cap
- $310.7M
- $191.82B
- 1M return
- +4.83%
- -10.44%
- 1Y return
- +199.86%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 0
- 8
- Recent ratings
- 22
- 25
Mersana Therapeutics Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MRSN
- SEC Form 15-12G filed by Mersana Therapeutics Inc.
- SEC Form EFFECT filed by Mersana Therapeutics Inc.
- Director Hack Andrew A. F. closing all direct ownership in the company (SEC Form 4)
- Director Hege Kristen closing all direct ownership in the company (SEC Form 4)
- Director Diaz Allene M. closing all direct ownership in the company (SEC Form 4)
- Director Dere Willard H closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Legal Officer Carvajal Alejandra closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Development Bala Mohan closing all direct ownership in the company (SEC Form 4)
- Director Alleva Lawrence M closing all direct ownership in the company (SEC Form 4)
- President, CEO Huber Martin H. Jr. closing all direct ownership in the company (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care